165 related articles for article (PubMed ID: 8912372)
21. A phase I/II study of 131I mIBG in chemo-resistant neuroblastoma. The United Kingdom Children's Cancer Study Group (UKCCSG).
Lewis IJ; Lashford LS; Fielding S; Flower MA; Ackery D; Kemshead J
Prog Clin Biol Res; 1991; 366():463-9. PubMed ID: 2068161
[No Abstract] [Full Text] [Related]
22. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
23. Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance.
Wafelman AR; Nortier YL; Rosing H; Maessen HJ; Taal BG; Hoefnagel CA; Maes RA; Beijnen JH
Nucl Med Commun; 1995 Sep; 16(9):767-72. PubMed ID: 7478409
[TBL] [Abstract][Full Text] [Related]
24. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.
Willegaignon J; Crema KP; Oliveira NC; Pelissoni RA; Coura-Filho GB; Sapienza MT; Buchpiguel CA
Clin Nucl Med; 2018 Aug; 43(8):572-578. PubMed ID: 29916922
[TBL] [Abstract][Full Text] [Related]
25. Treatment of neuroblastoma with 131I-MIBG: dosimetric problems and perspectives.
Beierwaltes WH
Med Pediatr Oncol; 1987; 15(4):188-91. PubMed ID: 3657705
[TBL] [Abstract][Full Text] [Related]
26. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.
Vaidyanathan G; Zhao XG; Strickland DK; Zalutsky MR
J Nucl Med; 1997 Feb; 38(2):330-4. PubMed ID: 9025764
[TBL] [Abstract][Full Text] [Related]
27. [Follow-up evaluation of metastatic neuroblastoma using high dose [131I-meta]iodobenzylguanidine].
Klingebiel T; Reuland P; Feine U; Niethammer D
Nuklearmedizin; 1992 Dec; 31(6):209-12. PubMed ID: 1491958
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic use of 131I-metaiodobenzylguanidine (MIBG) in neuroblastoma: a phase II study in nine patients.
Hartmann O; Lumbroso J; Lemerle J; Schlumberger M; Ricard M; Aubert B; Coonaert S; Merline L; Olive D; De Lumley L
Med Pediatr Oncol; 1987; 15(4):205-11. PubMed ID: 3657709
[TBL] [Abstract][Full Text] [Related]
29. 131I-meta-iodobenzylguanidine in diagnosis and treatment of neuroblastoma.
Voûte PA; Hoefnagel CA; de Kraker J
Bull Cancer; 1988; 75(1):107-11. PubMed ID: 3359053
[TBL] [Abstract][Full Text] [Related]
30. Enhanced therapeutic tumour dose of 131I-MIBG by accelerated diuresis.
Darte L; Tennvall J
Eur J Nucl Med; 1988; 14(9-10):512-4. PubMed ID: 3215192
[TBL] [Abstract][Full Text] [Related]
31. Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine.
Sisson JC; Shapiro B; Hutchinson RJ; Carey JE; Zasadny KR; Zempel SA; Normolle DP
Eur J Nucl Med; 1994 Jan; 21(1):46-52. PubMed ID: 8088285
[TBL] [Abstract][Full Text] [Related]
32. The treatment of neuroblastoma with [131I]MIBG at diagnosis.
Troncone L; Rufini V; Luzi S; Mastrangelo R; Riccardi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):65-8. PubMed ID: 9002753
[TBL] [Abstract][Full Text] [Related]
33. The treatment of neuroblastoma with 131I-MIBG.
Mastrangelo R
Med Pediatr Oncol; 1987; 15(4):157-8. PubMed ID: 3657703
[No Abstract] [Full Text] [Related]
34. Considerations on 131I-metaiodobenzylguanidine therapy of six children with neuroblastoma.
Sanguineti M
Med Pediatr Oncol; 1987; 15(4):212-5. PubMed ID: 3657710
[TBL] [Abstract][Full Text] [Related]
35. [Dosimetry for therapeutic treatment of neuroblastoma by 131I-mIBG].
Sudbrock F; Eschner W; Schmidt M; Simon T; Hero B; Schicha H
Nuklearmedizin; 2006; 45(6):254-61. PubMed ID: 17149494
[TBL] [Abstract][Full Text] [Related]
36. HIGH-DOSE 131I-MIBG THERAPIES IN CHILDREN: FEASIBILITY, PATIENT DOSIMETRY AND RADIATION EXPOSURE TO WORKERS AND FAMILY CAREGIVERS.
Cougnenc O; Defachelles AS; Carpentier P; Lervat C; Clisant S; Oudoux A; Kolesnikov-Gauthier H
Radiat Prot Dosimetry; 2017 Apr; 173(4):395-404. PubMed ID: 26940442
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic implications of the uptake of radiolabelled mIBG for the treatment of neuroblastoma.
O'Donoghue JA; Wheldon TE; Babich JW; Moyes JS; Barrett A; Meller ST
Prog Clin Biol Res; 1991; 366():455-61. PubMed ID: 2068160
[No Abstract] [Full Text] [Related]
38. Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes.
Weber W; Weber J; Senekowitsch-Schmidtke R
Cancer Res; 1996 Dec; 56(23):5428-34. PubMed ID: 8968097
[TBL] [Abstract][Full Text] [Related]
39. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
[TBL] [Abstract][Full Text] [Related]
40. 131-Metaiodobenzylguanedine therapy of neuroblastoma in childhood. One year of therapeutic experience.
Schwabe D; Sahm S; Gerein V; Happ J; Kropp-von Rabenau H; Maul F; Baum RP; Manegold K; Nitz C; Hör G
Eur J Pediatr; 1987 May; 146(3):246-50. PubMed ID: 3595643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
